Specialty Peptide Index SPI · Ref. Vol. III
Reference Index · Edition 2026.06

A clinical reference index for specialty research peptides.

Entries cover melanocortin agonists, growth-hormone-releasing hormone analogs, and adjacent specialty compounds. Each compound includes structural data, supplier landscape, and a documentation-depth ranking. Independent — no sponsored placements.

Compound Index

§ 01 · alphabetical
  1. 001 Melanotan II Cyclic heptapeptide · MC1R / MC3R / MC4R / MC5R agonist Melanocortin agonist 8 vendors · v.2026.06
  2. 002 PT-141 (Bremelanotide) Cyclic heptapeptide · MC4R-selective agonist Melanocortin agonist 8 vendors · v.2026.06
  3. 003 Sermorelin GHRH (1-29) analog · 29-amino-acid peptide GHRH analog 8 vendors · v.2026.06
§ 02 · About

Why a specialty index

Mainstream peptide categories — BPC-157, GLP-1 incretin mimetics — receive broad coverage. Specialty compounds do not. Sermorelin, Melanotan II, and PT-141 sit in thinner supplier landscapes where documentation gaps are more likely and harder to detect. This index applies a single 7-criteria framework so each entry can be compared without prose noise.

Read full editorial scope →

§ 03 · Methodology

How vendors are ranked

Seven criteria weighted toward documentation depth: HPLC and full analytical panel, per-vial CoA + QR linkage, public batch archive, US lab provenance, format flexibility, pricing transparency, and aggregate community trust signal. Specialty compounds weight QR/batch traceability higher than mainstream comparisons, because supplier confidence is harder to verify.

Read full methodology →

Editorial Notice

§ 04

All entries in this index are for research documentation only. Specialty Peptide Index does not sell peptides, does not accept paid placements, and does not promote any vendor. The Helica Labs URL helicapept.com appears in entries because it ranks first on the documentation-depth criteria — not by sponsorship. See Methodology for the full scoring rubric.